Shopping Cart
- Remove All
 
Your shopping cart is currently empty
Anti-TSPAN8 Antibody (6V251) is an antibody targeting TSPAN8. Anti-TSPAN8 Antibody (6V251) can be used in ELISA.
| Pack Size | Price | Availability | Quantity | 
|---|---|---|---|
| 50 μL | $209 | 7-10 days | |
| 100 μL | $348 | 7-10 days | 
| Description | Anti-TSPAN8 Antibody (6V251) is an antibody targeting TSPAN8. Anti-TSPAN8 Antibody (6V251) can be used in ELISA.  | 
| Ig Type | hIgG1  | 
| Clone | 6V251  | 
| Reactivity | Human  | 
| Verified Activity | 1. The Binding Activity of TSPAN8 with Anti-TSPAN8 recombinant antibody Activity: Measured by its binding ability in a functional ELISA. Immobilized Human TSPAN8 at 5 μg/mL can bind Anti-TSPAN8 recombinant antibody. The EC50 is 2.261-2.623 ng/mL.The VLPs is negative control. 2. Untransfected MC38 cells (green line) and transfected Human TSPAN8 MC38 stable cells (red line) were stained with anti-TSPAN8 antibody (TMAH-01221) (2µg/1*10^6 cells), washed and then followed by FITC-conjugated anti-Human IgG Fc antibody and analyzed with flow cytometry. 3. The purity of TSPAN8 was greater than 95% as determined by SEC-HPLC  | 
| Application | |
| Recommended Dose | ELISA:1:5000-1:50000.  | 
| Antibody Type | Monoclonal  | 
| Subcellular Localization | Membrane; Multi-pass membrane protein. | 
| Tissue Specificity | Gastric, colon, rectal, and pancreatic carcinomas. | 
| Construction | Recombinant Antibody | 
| Purification | Affinity-chromatography | 
| Appearance | Liquid | 
| Formulation | Preservative: 0.03% Proclin 300. Constituents: 50% Glycerol, 0.01M PBS, PH 7.4. | 
| Conjucates | Unconjugated  | 
| Immunogen | Recombinant Protein: Human TSPAN8 Protein  | 
| Antigen Species | Human  | 
| Gene Name | TSPAN8  | 
| Gene ID | |
| Uniprot ID | |
| Biology Area | Cancer, Tags & Cell Markers, Signal transduction  | 
| Stability & Storage | Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. | 
| Transport | Shipping with blue ice. | 

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.